Physician profile
Jurate Kunickaite
NPI 1013320100
$4,259.38
in general payments reported to CMS, 2019-2025
20 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,495 · 2021: $597 · 2022: $242 · 2023: $325 · 2024: $846 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $803.43 | 2019-2025 | Breztri, Airsupra |
| Amgen INC. | $801.87 | 2019-2023 | Repatha |
| Lilly USA, LLC | $513.92 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $452.82 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $336.95 | 2019-2025 | |
| Axsome Therapeutics, INC. | $223.77 | 2025 | Symbravo |
| Amarin Pharma, INC. | $190.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.16 | 2019-2021 | |
| Novo Nordisk INC | $156.66 | 2019 | |
| Glaxosmithkline, LLC. | $119.22 | 2024 | Arexvy |
| Pfizer INC. | $118.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $92.16 | 2019 | |
| Astellas Pharma US INC | $71.85 | 2019 | |
| Sunovion Pharmaceuticals INC. | $58.32 | 2019 | |
| Mylan Specialty L.P. | $37.81 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $26.31 | 2024 | Tremfya |
| Merck Sharp & Dohme LLC | $22.66 | 2019 | |
| Abbott Laboratories | $22.41 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jurate Kunickaite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.